Individualised Dose Optimisation of Ganciclovir in Immunocompromised Children Trial (ID-MAGIC)
This study is being conducted at seven major children's hospitals in Australia and New Zealand to test a new approach for treating a virus, called cytomegalovirus in children with weakened immune systems. The researchers want to find out if using a web app to customise the dose of a medication called ganciclovir is better at clearing the virus over a six-week period compared to the standard method of giving the medication.
Immunocompromised patients including transplant recipients (haematopoietic stem... [+5]
Current or prior CMV infection with documented genotypic resistance to GCV (UL97... [+8]